Drug Comparisons · Obesity & Diabetes Medications

📊 Drug Comparisons

Obesity & Diabetes Medications · Evidence‑Based Comparisons of GLP‑1 Agonists, Dual Agonists, and Triple Agonists
TL;DR · This page provides evidence‑based comparisons of the leading medications for obesity and type 2 diabetes. Based on recent network meta‑analyses and clinical trial data, retatrutide (triple GLP‑1/GIP/glucagon agonist) achieves the greatest weight loss (~24–25% at 48 weeks), followed by tirzepatide (dual GLP‑1/GIP agonist, ~20–21%) and semaglutide (GLP‑1 agonist, ~15%) . For glycemic control, tirzepatide leads in HbA1c reduction (−1.88%) and fasting blood glucose (−57.3 mg/dL) . Bimagrumab + semaglutide combination therapy achieves 22.1% weight loss with 92.9% from fat and minimal lean mass loss . MariTide (once‑monthly GIP antagonist/GLP‑1 agonist antibody‑peptide conjugate) achieves ~20% weight loss . Amycretin (GLP‑1/amylin co‑agonist) shows 24.3% weight loss in Phase 1b/2a trials . Emerging agents like CagriSema (semaglutide + cagrilintide) and orforglipron (oral non‑peptide) are in late‑stage development .

📑 Contents

Overview Weight Loss Comparison Glycemic Control Comparison Safety & Side Effects Combination Therapies Emerging Agents Muscle Loss Considerations FAQs Disclosure & Disclaimer

Overview

The landscape of obesity and diabetes pharmacotherapy has evolved rapidly, with multiple agents now available or in late‑stage development. This page provides evidence‑based comparisons based on recent network meta‑analyses and clinical trial data [citation:1][citation:2][citation:5].

📊 “Understanding the comparative efficacy and safety of these agents is essential for personalised treatment decisions.”

Weight Loss Comparison

A 2025 network meta‑analysis of 19 RCTs (29,506 participants) compared weight loss efficacy at ≥36 weeks [citation:5]. Another analysis of 25 RCTs (15,913 participants) evaluated weight loss at 1–1.5 years [citation:2].

24.2%
Retatrutide (12 mg, 48 wks)
20.9%
Tirzepatide (15 mg, 72 wks)
14.9%
Semaglutide (2.4 mg, 68 wks)
22.1%
Bimagrumab + Semaglutide (72 wks)
~20%
MariTide (52 wks)
Agent Mechanism Dosing Weight Loss (vs Placebo) SUCRA Rank
Retatrutide GLP‑1/GIP/Glucagon triple agonist Weekly SC −24.2% at 48 wks [citation:1] 97.9% [citation:1]
Tirzepatide GLP‑1/GIP dual agonist Weekly SC −20.9% at 72 wks [citation:14] 93.4% [citation:1]
Semaglutide GLP‑1 agonist Weekly SC −14.9% at 68 wks [citation:14] 72.8% [citation:1]
Survodutide GLP‑1/Glucagon dual agonist Weekly SC −4.6 kg (estimated) [citation:1] 75.5% [citation:1]
Mazdutide GLP‑1/Glucagon dual agonist Weekly SC −3.0 kg (estimated) [citation:1] 61.6% [citation:1]
Liraglutide GLP‑1 agonist Daily SC −8.0% at 56 wks [citation:14] —
📈 “Retatrutide ranked highest for weight loss in both the 6‑month and 1‑1.5 year analyses, followed by tirzepatide and semaglutide.” [citation:2]

Glycemic Control Comparison

For patients with type 2 diabetes, glycemic control is a key outcome. A network meta‑analysis of 22 trials (10,220 patients) evaluated HbA1c and fasting blood glucose (FBG) reductions [citation:1].

Agent HbA1c Reduction (vs Placebo) FBG Reduction (mg/dL) SUCRA Rank (HbA1c)
Tirzepatide −1.88% [citation:1] −57.30 [citation:1] 90.6%
Semaglutide −1.5% (estimated) [citation:14] — 72.8%
Retatrutide −2.02% (Phase 2 T2D) — —
Cotadutide — — —
🩸 “Tirzepatide demonstrated the most significant reduction in HbA1c and FBG among incretin‑based therapies.” [citation:1]

Safety & Side Effects

Gastrointestinal side effects are the most common across all incretin‑based therapies. The network meta‑analysis assessed adverse event (AE) and serious adverse event (SAE) risks [citation:1].

  • Tirzepatide: RR 1.15 for AEs (95% CrI 1.04–1.33) [citation:1]
  • Cotadutide: RR 1.38 for AEs (95% CrI 1.16–1.68) [citation:1]
  • Semaglutide: RR 0.35 for SAEs (95% CrI 0.13–0.78) [citation:1]
  • Retatrutide: Highest AE risk among agents [citation:5]
  • Bimagrumab + semaglutide: Common AEs include muscle spasms (46–74%), diarrhea, and acne; no deaths reported [citation:7][citation:15]

Retatrutide’s AE risk is higher than dual agonists, which may offer a more favourable efficacy–safety balance [citation:5].

⚠️ “Retatrutide offers superior weight loss but with a higher AE risk. Dual agonists provide a favourable efficacy–safety balance.” [citation:5]

Combination Therapies

The Phase 2b BELIEVE trial evaluated bimagrumab (activin type II receptor blocker) combined with semaglutide [citation:3][citation:7][citation:15].

🧬 Bimagrumab + Semaglutide (BELIEVE)
Activin receptor blockade + GLP‑1 agonism
Phase 2b
Weight loss: 22.1% at 72 weeks
Fat loss: 92.9% of weight loss from fat
Lean mass: −2.9% (vs −7.4% with semaglutide alone)
Waist circumference: −21.7 cm
💉 CagriSema (Novo Nordisk)
Semaglutide + cagrilintide (amylin analog)
Phase 3
Weight loss: ~20‑23% (estimated) [citation:10]
Note: Phase 3 REDEFINE‑2 showed 13.7% weight loss, below investor expectations [citation:11]
💪 “Bimagrumab + semaglutide combination therapy addresses the muscle loss concern associated with GLP‑1 drugs while enhancing fat loss.” [citation:3]

Emerging Agents

Agent Mechanism Estimated Weight Loss Status
Amycretin GLP‑1/amylin co‑agonist 24.3% (SC, 36 wks) Phase 2 [citation:14]
MariTide GIP antagonist + GLP‑1 ADC ~20% (52 wks) Phase 3 [citation:11][citation:14]
Orforglipron Oral non‑peptide GLP‑1 ~11‑15% Phase 3 [citation:10]
Petrelintide Amylin agonist ~8.6% (16 wks) Phase 2b [citation:11]
🚀 “Emerging agents like amycretin and MariTide offer new mechanisms and the potential for once‑monthly dosing.” [citation:11][citation:14]

Muscle Loss Considerations

One of the key concerns with GLP‑1‑based weight loss is the proportion of weight loss coming from lean mass. Data from clinical trials highlight the differences between agents [citation:9].

Agent Weight Loss Lean Mass Loss (% of total weight loss)
Semaglutide 2.4 mg −14.9% 39% [citation:9]
Tirzepatide 15 mg −20.9% 24% [citation:9]
Retatrutide 12 mg −22.8% 33% (T2D trial) [citation:9]
Bimagrumab + Semaglutide −22.1% ~7% [citation:3]
Bimagrumab alone −10.8% +2.5% (gain) [citation:3]
🦴 “Muscle loss is an emerging concern with GLP‑1 drugs. New agents and combinations aim to preserve lean mass.” [citation:9]

The comparative data clearly show a hierarchy of efficacy, with multi‑targeting agents outperforming single GLP‑1 agonists for weight loss and, in some cases, glycemic control. However, the choice of therapy must be individualised based on a patient’s specific goals, comorbidities, and tolerability. Emerging agents and combination strategies offer the promise of even greater efficacy with improved body composition outcomes. As the evidence base continues to grow, regular updates to these comparisons will be essential for clinical practice.

❓ FAQs About Drug Comparisons

Which drug causes the most weight loss?
Retatrutide (triple agonist) achieves the greatest weight loss at ~24–25% at 48 weeks, followed by tirzepatide (~20–21%) and semaglutide (~15%) [citation:1][citation:2].
Which drug is best for blood sugar control?
Tirzepatide demonstrated the most significant reduction in HbA1c (−1.88%) and FBG (−57.3 mg/dL) among incretin‑based therapies [citation:1].
Do these drugs cause muscle loss?
Yes. Semaglutide caused 39% of weight loss from lean mass, tirzepatide 24%, and retatrutide 33% in a T2D trial. Bimagrumab + semaglutide reduced this to ~7% [citation:3][citation:9].
What is the difference between dual and triple agonists?
Dual agonists target two receptors (e.g., GLP‑1 and GIP). Triple agonists target three (e.g., GLP‑1, GIP, and glucagon). Additional targets can enhance weight loss and metabolic effects [citation:1].
Is retatrutide FDA‑approved?
No. Retatrutide is investigational and in Phase 3 trials. It is not yet FDA‑approved.
What is the best combination therapy?
Bimagrumab + semaglutide achieved 22.1% weight loss with 92.9% from fat and minimal lean mass loss in Phase 2 trials [citation:3][citation:7].
Which agent has the best safety profile?
Semaglutide had the lowest risk of serious adverse events (RR 0.35) in a network meta‑analysis. Dual agonists offer a more favourable efficacy–safety balance than triple agonists [citation:1][citation:5].

📌 Disclosure & Disclaimer

Disclosure: This article is for educational and informational purposes only. The author has no financial ties to any pharmaceutical companies mentioned. References reflect current scientific literature and regulatory documents, not endorsements.

Disclaimer: This content does not constitute medical advice, diagnosis, or treatment. Drug comparisons should be interpreted by qualified healthcare professionals. Always consult your physician before starting or changing any medication.

📊 PS — Evidence‑Based Decision Making
The obesity and diabetes treatment landscape is evolving rapidly. Stay informed with the latest evidence, but always remember that individual patient factors—comorbidities, tolerability, preferences, and cost—should guide treatment choices. Network meta‑analyses and head‑to‑head trials provide the strongest evidence for comparative efficacy.

Trust the data. Personalise the care.

The right drug for the right patient at the right time.

✧ Written in service of evidence‑based medicine and patient safety ✧